Hansen Suzanne L, Sperling Bonnie B, Sánchez Connie
Department of Neuropharmacology, H. Lundbeck A/S, Ottiliavej 9, DK-2500 Copenhagen-Valby, Denmark.
Prog Neuropsychopharmacol Biol Psychiatry. 2004 Jan;28(1):105-13. doi: 10.1016/j.pnpbp.2003.09.026.
Although animal models based on pentylenetetrazole (PTZ) are widely used, the mechanism by which PTZ elicits its action is not very well understood. At the molecular level, a generally accepted mechanism of PTZ is noncompetitive antagonism of the gamma-aminobutyric acid (GABA)(A) receptor complex. By a systematic pharmacological investigation of various GABA(A) receptor ligands, our aim was to gain a better understanding of the GABAergic mechanisms involved in different PTZ-induced seizures. We investigated anticonvulsant effects of various specific GABA(A) receptor ligands, which are believed to bind to different binding sites on the GABA(A) receptor complex, on PTZ-induced clonic seizures in drug naive and PTZ-kindled mice as well as their effects on the development of PTZ kindling. Diazepam and alphaxalone produced potent anticonvulsant effects and completely suppressed the development of kindling. In contrast, the antagonists bicuculline and dehydroepiandrosterone sulfate (DHEAS) displayed neither anticonvulsant nor antiepileptogenic effects. Flumazenil, often used as a reference antagonist at the GABA(A) receptor benzodiazepine (BZ) binding site, lacked anticonvulsant effects but surprisingly inhibited the development of PTZ-kindled seizures. The agonist 4,5,6,7-tetrahydroisoxazolo-(5,4-c)pyridin-3-ol (THIP) was devoid of both anticonvulsant and antiepileptogenic effects. Marked differences in drug sensitivity were observed between models based on single and chronic administration of PTZ showing that the two sets of models are fundamentally different. These results describe the pharmacology of a set of ligands believed to bind to different sites at the GABA(A) receptor complex in animal models based on PTZ and demonstrate that a drug's action in these models cannot be readily explained by agonistic or antagonistic properties at the receptor level.
尽管基于戊四氮(PTZ)的动物模型被广泛使用,但其引发作用的机制尚未完全明确。在分子水平上,普遍认为PTZ的作用机制是对γ-氨基丁酸(GABA)(A)受体复合物的非竞争性拮抗。通过对各种GABA(A)受体配体进行系统的药理学研究,我们旨在更好地理解不同PTZ诱导的癫痫发作中涉及的GABA能机制。我们研究了各种特异性GABA(A)受体配体对PTZ诱导的阵挛性癫痫发作的抗惊厥作用,这些配体被认为与GABA(A)受体复合物上的不同结合位点结合,同时研究了它们对药物未处理小鼠和PTZ点燃小鼠的PTZ诱导阵挛性癫痫发作以及对PTZ点燃发展的影响。地西泮和alphaxalone产生了强大的抗惊厥作用,并完全抑制了点燃的发展。相比之下,拮抗剂荷包牡丹碱和硫酸脱氢表雄酮(DHEAS)既没有抗惊厥作用也没有抗癫痫作用。氟马西尼通常用作GABA(A)受体苯二氮䓬(BZ)结合位点的参考拮抗剂,缺乏抗惊厥作用,但令人惊讶的是它抑制了PTZ点燃癫痫发作的发展。激动剂4,5,6,7-四氢异恶唑并[5,4-c]吡啶-3-醇(THIP)既没有抗惊厥作用也没有抗癫痫作用。在基于单次和长期给予PTZ的模型之间观察到明显的药物敏感性差异,表明这两组模型在根本上是不同的。这些结果描述了一组被认为与基于PTZ的动物模型中GABA(A)受体复合物不同位点结合的配体的药理学特性,并证明在这些模型中药物的作用不能简单地通过受体水平的激动或拮抗特性来解释。